SU14813 is primarily used in cancer research due to its ability to inhibit multiple receptor tyrosine kinases involved in tumor growth and angiogenesis. It targets kinases such as VEGFR2, PDGFRβ, and c-Kit, making it a valuable tool for studying signaling pathways in various cancers. Its multi-target profile allows researchers to investigate the effects of simultaneous pathway inhibition on tumor progression and vascular development in preclinical models. SU14813 has shown activity in models of renal cell carcinoma and other solid tumors, supporting its use as a probe compound in oncology drug development.